Evidence map›Paper›PMID 10871732›Full record

ReviewBone marrow transplantation2000

Mucosal barrier injury: biology, pathology, clinical counterparts and consequences of intensive treatment for haematological malignancy: an overview.

N M Blijlevens, J P Donnelly, B E De Pauw

Registry-linked trialOpen access · greenAbstract readReview
PubMed Full text at PMC Publisher
In one paragraph

Review in Bone marrow transplantation, 2000. The graph could read no effect estimate from its abstract, so it casts no vote on the map. It is linked to trial NCT06940570 (A Randomized Single Center Trial to Determine the Efficacy of Methadone as a First Line Agent in the Reduction and Treatment of Pain in Pediatric Patients Undergoing Hematopoietic Stem Cell Transplantation), which is not on this map. Cited by 82 papers, 1 of them a synthesis that pooled it.

0numbers the graph read from it
0cells of the map it votes in
82citing papers in PubMed, 1 pooled it
7.4field-weighted citation impact, top 3% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

NCT06940570 phase3suspendednot on this mapstarted 2028, after this paper: background citation

A Randomized Single Center Trial to Determine the Efficacy of Methadone as a First Line Agent in the Reduction and Treatment of Pain in Pediatric Patients Undergoing Hematopoietic Stem Cell Transplantation

TypeinterventionalSponsorUniversity of Texas Southwestern Medical CenterRan2028 to 2029Enrolled60ConditionsLeukemia, Aplastic Anemia, Bone Marrow Failure Syndromes, SCIDArmsPCA plus methadone (Experimental), PCA Alone (SOC)
3 · Its place in the literature

Who cites it

82 citing papers in PubMed, 1 synthesis or guideline pooled it, 265 citations in OpenAlex.

  1. Systematic review of agents for the management of cancer treatment-related gastrointestinal mucositis and clinical practice guidelines.Supportive care in cancer : official journal of the Multinational Association of Supportive Care in Cancer · 2019
    Pooled it
  2. Trial
  3. Trial
  4. Trial
  5. Trial
  6. Trial
  7. A randomised, double-blinded, placebo-controlled, pilot study of parenteral glutamine for allogeneic stem cell transplant patients.Supportive care in cancer : official journal of the Multinational Association of Supportive Care in Cancer · 2005
    Trial
  8. Trial
  9. Review
  10. Article
  11. Article
  12. Barriers and facilitators in oral hygiene maintenance in children undergoing chemotherapy for acute lymphoblastic leukemia: a qualitative investigation.European archives of paediatric dentistry : official journal of the European Academy of Paediatric Dentistry · 2026
    Article
  13. Article
  14. Article
  15. Observational
  16. Review
  17. Article
  18. Article
  19. Review
  20. Article

22 more citing papers are in PubMed but not listed here.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

3 authors at 2 institutions in 1 country.

N M BlijlevensDepartment of Hematology, University Medical Center St Radboud, Nijmegen, The Netherlands.
J P Donnelly
B E De Pauw
Radboud University Medical Center · NLRadboud University Nijmegen · NL

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Mucositis is an inevitable side-effect of the conditioning regimens used for haematopoietic stem cell transplantation. The condition is better referred to as mucosal barrier injury (MBI) since it is primarily the result of toxicity and is a complex and dynamic pathobiological process manifested not only in the mouth but also throughout the entire digestive tract. A model has been proposed for oral MBI and consists of four phases, namely inflammatory, epithelial, ulcerative and healing phases. A variety of factors are involved in causing and modulating MBI including the nature of the conditioning regimen, the elaboration of pro-inflammatory and other cytokines, translocation of the resident microflora and their products, for example, endotoxins across the mucosal barrier, exposure to antimicrobial agents and whether or not the haematopoietic stem cell graft is from a donor. Neutropenic typhlitis is the most severe gastrointestinal manifestation of MBI, but it also influences the occurrence of other major transplant-related complications including acute GVHD, veno-occlusive disease and systemic infections. The pathobiology, clinical counterparts and the means of measuring MBI are discussed together with potential approaches for prevention, amelioration and, perhaps, even cure. Bone Marrow Transplantation (2000) 25, 1269-1278.

Indexed as

Hematologic NeoplasmsHematopoietic Stem Cell TransplantationHumansImmunity, MucosalMouth MucosaStomatitis

Identifiers

PMID10871732
PMCPMC7091624
OpenAlexW1985482871

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.